ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Gene Therapy

Taysha launches with $30 million and 15 gene therapy programs

by Ryan Cross
May 2, 2020 | APPEARED IN VOLUME 98, ISSUE 17

 

Taysha Gene Therapies made a bold debut with $30 million in seed financing and a pipeline of 15 preclinical gene therapies for diseases of the central nervous system. The Dallas-based start-up will rely on the University of Texas Southwestern Medical Center’s gene therapy program—led by Steven Gray and Berge Minassian—for drug discovery, preclinical research, and clinical manufacturing of adeno-associated virus-based gene therapies. Sean Nolan, former CEO of AveXis, which makes the gene therapy Zolgensma, leads Taysha’s board of directors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment